Horizon Therapeutics Public Limited Company [NASDAQ: HZNP] stock went on an upward path that rose over 0.70% on Friday, amounting to a one-week price increase of more than 1.66%. The company report on December 3, 2020 that Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education.
Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has provided $500,000 in scholarships to Lake Forest College and created a $500,000 Horizon Therapeutics Endowed Scholarship Fund at Howard University. The scholarships at both institutions will be awarded to economically disadvantaged students and students of color.
“Equity in education is a significant global issue and we feel it is important for companies and individuals who have the resources to help remove obstacles that exist for marginalized populations,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Financial support is an important step, but in order to make an ongoing impact, it is also our responsibility to provide mentoring, internship and post-graduate employment opportunities. We look forward to developing long-term partnerships with Lake Forest College, Rosalind Franklin University and Howard University and building a global network of Horizon Scholars.”.
Over the last 12 months, HZNP stock rose by 119.87%. The one-year Horizon Therapeutics Public Limited Company stock forecast points to a potential upside of 28.76. The average equity rating for HZNP stock is currently 1.60, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $15.72 billion, with 220.71 million shares outstanding and 218.00 million shares in the current float. Compared to the average trading volume of 2.51M shares, HZNP stock reached a trading volume of 3012962 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Horizon Therapeutics Public Limited Company [HZNP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HZNP shares is $100.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HZNP stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Horizon Therapeutics Public Limited Company shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 09, 2020. While these analysts kept the previous recommendation, Citigroup raised their target price to Buy. The new note on the price target was released on August 27, 2020, representing the official price target for Horizon Therapeutics Public Limited Company stock. Previously, the target price had yet another raise to $35, while Goldman analysts kept a Neutral rating on HZNP stock.
The Average True Range (ATR) for Horizon Therapeutics Public Limited Company is set at 3.15, with the Price to Sales ratio for HZNP stock in the period of the last 12 months amounting to 8.64. The Price to Book ratio for the last quarter was 4.01, with the Price to Cash per share for the same quarter was set at 7.87. Price to Free Cash Flow for HZNP in the course of the last twelve months was 79.63 with Quick ratio for the last quarter at 3.40.
HZNP Stock Performance Analysis:
Horizon Therapeutics Public Limited Company [HZNP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.66. With this latest performance, HZNP shares dropped by -11.37% in over the last four-week period, additionally plugging by 46.34% over the last 6 months – not to mention a rise of 119.87% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HZNP stock in for the last two-week period is set at 47.42, with the RSI for the last a single of trading hit 52.32, and the three-weeks RSI is set at 47.67 for Horizon Therapeutics Public Limited Company [HZNP]. The present Moving Average for the last 50 days of trading for this stock 75.65, while it was recorded at 70.29 for the last single week of trading, and 56.97 for the last 200 days.
Insight into Horizon Therapeutics Public Limited Company Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Horizon Therapeutics Public Limited Company [HZNP] shares currently have an operating margin of +10.76 and a Gross Margin at +72.14. Horizon Therapeutics Public Limited Company’s Net Margin is presently recorded at +44.08.
Return on Total Capital for HZNP is now 4.28, given the latest momentum, and Return on Invested Capital for the company is 17.54. Return on Equity for this stock inclined to 35.38, with Return on Assets sitting at 13.35. When it comes to the capital structure of this company, Horizon Therapeutics Public Limited Company [HZNP] has a Total Debt to Total Equity ratio set at 64.23. Additionally, HZNP Total Debt to Total Capital is recorded at 39.11, with Total Debt to Total Assets ending up at 31.64. Long-Term Debt to Equity for the company is recorded at 64.03, with the Long-Term Debt to Total Capital now at 38.99.
Reflecting on the efficiency of the workforce at the company, Horizon Therapeutics Public Limited Company [HZNP] managed to generate an average of $477,517 per employee. Receivables Turnover for the company is 2.98 with a Total Asset Turnover recorded at a value of 0.30.Horizon Therapeutics Public Limited Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.40 and a Current Ratio set at 3.50.
HZNP Stock EPS
With the latest financial reports released by the company, Horizon Therapeutics Public Limited Company posted 0.56/share EPS, while the average EPS was predicted by analysts to be reported at 0.42/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HZNP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Horizon Therapeutics Public Limited Company go to 30.10%.
Horizon Therapeutics Public Limited Company [HZNP] Insider Position Details
There are presently around $14,183 million, or 90.20% of HZNP stock, in the hands of institutional investors. The top three institutional holders of HZNP stocks are: VANGUARD GROUP INC with ownership of 19,252,850, which is approximately 8.439% of the company’s market cap and around 0.60% of the total institutional ownership; FMR LLC, holding 16,380,717 shares of the stock with an approximate value of $1.17 billion in HZNP stocks shares; and BLACKROCK INC., currently with $828.59 million in HZNP stock with ownership of nearly 2.13% of the company’s market capitalization.
Positions in Horizon Therapeutics Public Limited Company stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 272 institutional holders increased their position in Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] by around 33,561,451 shares. Additionally, 179 investors decreased positions by around 22,314,206 shares, while 20 investors held positions by with 141,885,826 shares. The mentioned changes placed institutional holdings at 197,761,483 shares, according to the latest SEC report filing. HZNP stock had 120 new institutional investments in for a total of 6,093,848 shares, while 39 institutional investors sold positions of 1,687,144 shares during the same period.